Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?

Abbott reported Q1 2026 CGM sales of $2.0B, up 7.5% year over year, and reiterated 2026 revenue growth guidance of 11% to 13%, but faces headwinds from weaker respiratory diagnostics, China softness and $0.20 EPS dilution from the Exact Sciences deal. DexCom is seeing broader CGM access, with more than 1 million users connected to automated insulin delivery systems, U.S. rollout of its G7 15 Day sensor and expanding coverage, including all three major U.S. PBMs covering its CGM for all diabetes patients. Year to date, ABT shares are down 25.6% versus DXCM up 4.1%, and the article frames DXCM more favorably on growth and valuation.

Analysis

The setup is less about “CGM growth vs CGM growth” and more about operating leverage quality. DXCM has the cleaner earnings trajectory because incremental adoption, reimbursement broadening, and the 15-day upgrade cycle should convert into higher gross margin mix with less portfolio distraction; ABT, by contrast, is still using CGM as one growth engine inside a much more heterogeneous earnings base, so the market is discounting noise in Diagnostics, China, and the Exact Sciences dilution until those drags fade. That makes DXCM the higher-beta beneficiary of any reacceleration in diabetes tech spending, while ABT is more of a self-help story that needs multiple moving parts to cooperate.

The second-order winner may actually be the automated insulin delivery ecosystem. As DexCom expands compatibility and device duration, it raises switching costs for pump partners and creates a platform moat that could pressure smaller sensor competitors and delay share gains from any late entrants. Abbott’s ketone/glucose dual-sensing concept is interesting defensively, but it is still a future monetization story; near term, it mainly underscores that ABT is trying to defend category relevance rather than monetize a clear upgrade cycle.

The main risk to the bearish ABT view is timing: if respiratory testing normalizes or China stabilizes faster than expected, the stock can rerate sharply because sentiment is already poor and the setup is washed out. For DXCM, the risk is that the market is already pricing a lot of the obvious upside from coverage expansion and the 15-day sensor conversion; if conversion stalls below management’s target or payer mix shifts slower than expected, the multiple can compress even with decent revenue growth. The cleanest catalyst window is the next 1-2 quarters, when reimbursement data and conversion metrics will tell us whether the current divergence is durable or just a temporary installation-base trade-up.

Key Decisions for Investors

• Go long DXCM on any post-earnings or guidance-related weakness over the next 1-4 weeks; target a 6-12 month hold if 15-day conversion and international reimbursement continue to inflect, with upside driven by multiple expansion from still-depressed historical levels.
• Short ABT as a relative underperformer for the next 1-3 months, or buy ABT puts into strength; thesis is that mixed segment execution and Exact Sciences dilution cap near-term upside even if CGM improves.
• Pair trade: long DXCM / short ABT at roughly 1:1 dollar exposure; this isolates the cleaner CGM operating leverage while hedging broad healthcare beta, with a better-than-2:1 reward/risk if the spread reverts toward the growth gap.
• For investors already long ABT, sell covered calls 1-2 quarters out to monetize the low-volatility, low-conviction setup while waiting for Diagnostics/China visibility to improve.
• Watch for a DXCM pullback to add only if the market overreacts to any short-term conversion noise; the key risk is paying up before the next proof point, so size the position with a stop on evidence of stalled payer or pump-partner traction.